<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1911">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04972643</url>
  </required_header>
  <id_info>
    <org_study_id>SF12109A</org_study_id>
    <nct_id>NCT04972643</nct_id>
  </id_info>
  <brief_title>The Protective Effect of Omega-3 Fatty Acid on Cognitive Function Among Patients With Mild Dementia</brief_title>
  <official_title>Department of Psychiatry, Taichung Veterans General Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taichung Veterans General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taichung Veterans General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background： Dementia is a progressive, devastating, and fatal neurodegenerative disorder.&#xD;
      Alzheimer's disease (AD) is the most common cause of dementia, accounting for more than 50%&#xD;
      of patients with dementia. Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), the&#xD;
      major bioactive components of n-3 polyunsaturated fatty acids (n-3 PUFAs) , might connect to&#xD;
      the etiology of several neuropsychiatric diseases. To our knowledge, it has never been&#xD;
      studied to look at the different effects of DHA, EPA and their combination on associated&#xD;
      symptoms of AD.&#xD;
&#xD;
      Objectives To examine the effects of DHA, EPA and their combination on associated symptoms of&#xD;
      AD, including cognitive function, depressive symptoms, and functional ability.&#xD;
&#xD;
      Method This is a randomized, double-blind, placebo-controlled, 24-month follow-up study,&#xD;
      enrolling 200-400 patients with mild AD (Mini-Mental Status Examination (MMSE) 19-26 or&#xD;
      Clinical Dementia Rating (CDR) 0.5-1). Cognitive ability is assessed by the Alzheimer Disease&#xD;
      Assessment Scale-Cognitive Subscale (ADAS-Cog) and the MMSE. Mood status is assessed by&#xD;
      Geriatric Depression Scale (GDS). Functional ability is assessed by the Alzheimer Disease&#xD;
      Cooperative Study activities of daily living (ADCS-ADL) and global function by the CDR,&#xD;
      quality of life scale (QOL-AD). Brain function is assessed by resting state brain magnetic&#xD;
      resonance imaging (MRI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background Dementia is a progressive, devastating, and fatal neurodegenerative disorder&#xD;
      (Cummings, 2004). As of 2010, there are an estimated 35.6 million people with dementia&#xD;
      worldwide. By 2050, it is projected that this figure will have increased to over 115 million&#xD;
      (1, 2). Therefore, dementia is not only an important medical disease but also a public health&#xD;
      issue to demand immediate attention. A conservative estimate of economic burden from dementia&#xD;
      (based on Alzheimer's Society's Dementia United Kindom (UK) report published in February&#xD;
      2007) reaches 20 billion by the year 2010, which suggests an average cost of 25,472 per&#xD;
      person annually. It indicated a heavy social financial expense for the whole world in&#xD;
      general. Alzheimer's disease (AD) is the most common cause of dementia, accounting for 60-80%&#xD;
      of patients with dementia. Given that it is still lacking in effective treatments for AD,&#xD;
      there has been growing interest in early detection and prevention for this disastrous&#xD;
      illness. Delaying AD onset by 1 year could potentially lower its incidence by more than 9&#xD;
      million cases over the next 40 years (3).&#xD;
&#xD;
      Dementia could be resulted from numerous risk factors and medical conditions including&#xD;
      vascular risk factors (e.g. hypertension, diabetes, and obesity), psychosocial factors (e.g.&#xD;
      depression), and health behaviors (e.g. physical inactivity and smoking) (4, 5). Indeed,&#xD;
      reflecting its heterogeneity, several hypotheses have been proposed for etiology of dementia,&#xD;
      including genetic susceptibility, vascular changes, inflammatory process, oxidative stress,&#xD;
      and recently, n-3 polyunsaturated fatty acids (n-3 PUFAs) (Fratiglioni et al., 2008;Samieri&#xD;
      et al., 2008;Cole and Frautschy, 2010;Mucke and Pitas, 2004;Gomez-Pinilla, 2008). PUFAs are&#xD;
      classified into mainly n-3 (or omega-3) and n-6 (or omega-6) groups. Docosahexaenoic acid&#xD;
      (DHA) and eicosapentaenoic acid (EPA), the major bioactive components of n-3 PUFAs, are&#xD;
      associated with neuronal membrane stability and fluidity, neurogenesis, neuroplasticity,&#xD;
      neurotransmission and anti-inflammation, which might connect to the etiology of several&#xD;
      neuropsychiatric diseases including depression and dementia (Horrobin and Bennett, 1999;Su et&#xD;
      al., 2000;Chalon, 2006;Lukiw and Bazan, 2006;Su, 2009b;Lin et al., 2010a). On the other hand,&#xD;
      arachidonic acid (AA), the major components of n-6 PUFAs, is a precursor of eicosanoids and&#xD;
      is important to modulate proinflammatory effects, which might also link to the pathogenesis&#xD;
      of neuroinflammatory and neurodegenerative diseases like dementia (Sanchez-Mejia and Mucke,&#xD;
      2010;Lukiw and Bazan, 2010). Consistent with the theoretical relevance, evidences to link&#xD;
      PUFAs to dementia have been reported extensively from more epidemiological studies. For&#xD;
      example, it has been observed that regions with a high consumption of fish, which are good&#xD;
      sources of n-3 PUFAs, appear to have a lower prevalence of dementia (Barberger-Gateau et al.,&#xD;
      2002;Barberger-Gateau et al., 2007;Huang et al., 2005;Morris et al., 2003;Kalmijn et al.,&#xD;
      1997) and Mild cognitive Impairment (MCI) ;(Roberts et al., 2010)). Although clinical studies&#xD;
      until now have failed to demonstrate beneficial effects of n-3 PUFA supplementation in&#xD;
      patients with moderate or severe AD (Freund-Levi et al., 2006a;Quinn et al., 2010a), it may&#xD;
      benefit in patients with mild AD or MCI and those without apolipoprotein E(APOE) ε4 allele&#xD;
      (Freund-Levi et al., 2006b;Chiu et al., 2008;Quinn et al., 2010b). In addition, the two main&#xD;
      n-3 PUFAs have different biological effects. DHA is the main n-3 PUFAs in the brain and is&#xD;
      important in neuroplasticity and neuroprotection. EPA, on the other hand, is very little in&#xD;
      the brain but is important in modulate inflammation and immune function (Lin et al.,&#xD;
      2010b;Su, 2009a). To our knowledge, it has never been studied to look at the different&#xD;
      effects of DHA, EPA and their combination on different associated symptoms of AD. To provide&#xD;
      more evidence for the association between n-3 PUFAs and associated symptoms of AD, including&#xD;
      cognitive function, depression, and physical activity in AD, we propose to conduct this&#xD;
      double-blind, placebo-controlled, 24-month research. In addition, neuroprotective effects of&#xD;
      vitamin B, preliminary findings in recent studies have shown cognitive-protection effects of&#xD;
      it among patients with MCI. Moreover, deficiency of vitamin B is known to cause nervousness,&#xD;
      depression, and peripheral and central neuropathy. The importance of vitamin B in&#xD;
      developmental processes of the brain is supported by the findings that vitamin B deficiency&#xD;
      at certain stages of brain development interferes with brain cell proliferation, migration&#xD;
      and maturation . Vitamin B affords survival-promoting activities on cultured brain neurons&#xD;
      (6). This is probably the first study to evaluate the effects of vitamin B on cognitive&#xD;
      protection among Asian patients with AD. Based on the review of the possible benefits from&#xD;
      n-3 PUFAs supplement on cognitive function preservation after balancing for its slightest&#xD;
      side effects, we here propose a randomized clinical trial study design to test whether&#xD;
      Hypothesis Omega-3 PUFAs is protective against cognitive decline among people with mild AD.&#xD;
&#xD;
      Primary Aim To examine whether consumption of n-3 PUFAs protects against cognitive decline in&#xD;
      patients with mild AD.&#xD;
&#xD;
      Secondary Aims&#xD;
&#xD;
        1. To examine the different effects of DHA, EPA and their combination on different symptoms&#xD;
           of AD.&#xD;
&#xD;
        2. To examine whether consumption of n-3 PUFAs improves cognitive function in patients with&#xD;
           mild AD.&#xD;
&#xD;
        3. To examine whether consumption of n-3 PUFAs improves depressive symptoms in patients&#xD;
           with mild AD.&#xD;
&#xD;
        4. To examine whether consumption of n-3 PUFAs improves physical activity level in patients&#xD;
           with mild AD.&#xD;
&#xD;
      Significance of Study&#xD;
&#xD;
        1. To provide a simple way through dietary supplement of n-3 PUFAs to prevent cognitive&#xD;
           decline and improve depressive symptoms and physical activity in patients with mild AD.&#xD;
&#xD;
        2. No placebo-controlled studies regarding n-3 PUFAs in cognitive prevention have been&#xD;
           conducted among Asian people.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 23, 2012</start_date>
  <completion_date type="Actual">September 23, 2018</completion_date>
  <primary_completion_date type="Actual">May 12, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aspartate Aminotransferase (AST)</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Aspartate Aminotransferase (AST)</measure>
    <time_frame>Day 24 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Alanine Aminotransferase (ALT)</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Alanine Aminotransferase (ALT)</measure>
    <time_frame>Day 24 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Albumin level</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Albumin level</measure>
    <time_frame>Day 24 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting blood glucose</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting blood glucose</measure>
    <time_frame>Day 24 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Urea Nitrogen (BUN)</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Urea Nitrogen (BUN)</measure>
    <time_frame>Day 24 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Creatinine level</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Creatinine level</measure>
    <time_frame>Day 24 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sodium (Na)</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sodium (Na)</measure>
    <time_frame>Day 24 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Potassium (K)</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Potassium (K)</measure>
    <time_frame>Day 24 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Calcium (Ca)</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Calcium (Ca)</measure>
    <time_frame>Day 24 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Magnesium (Mg)</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Magnesium (Mg)</measure>
    <time_frame>Day 24 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Triiodothyronine (T3)</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Triiodothyronine (T3)</measure>
    <time_frame>Day 24 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Free tetraiodothyronine (free T4)</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Free tetraiodothyronine (free T4)</measure>
    <time_frame>Day 24 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Thyroxin stimulating hormone (TSH)</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Thyroxin stimulating hormone (TSH)</measure>
    <time_frame>Day 24 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>Day 24 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>Day 24 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>High density lipoprotein cholesterol (HDL)</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>High density lipoprotein cholesterol (HDL)</measure>
    <time_frame>Day 24 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Low density lipoprotein cholesterol (LDL)</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Low density lipoprotein cholesterol (LDL)</measure>
    <time_frame>Day 24 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vitamine B12 level</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vitamine B12 level</measure>
    <time_frame>Day 24 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Folic acid</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Folic acid</measure>
    <time_frame>Day 24 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rapid plasma reagin for Syphilis test (RPR)</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rapid plasma reagin for Syphilis test (RPR)</measure>
    <time_frame>Day 24 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mini Mental Status Evaluation (MMSE) total score</measure>
    <time_frame>Day 0</time_frame>
    <description>Minimu:0, Maximum: 30, Higher scores mean a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mini Mental Status Evaluation (MMSE) total score</measure>
    <time_frame>Day 24 month</time_frame>
    <description>Minimu:0, Maximum: 30, Higher scores mean a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Dementia Rating Scale (CDR) total score</measure>
    <time_frame>Day 0</time_frame>
    <description>Minimu:0, Maximum: 3, Higher scores mean a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Dementia Rating Scale (CDR) total score</measure>
    <time_frame>Day 24 month</time_frame>
    <description>Minimu:0, Maximum: 3, Higher scores mean a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hachinski ischemic score total score</measure>
    <time_frame>Day 0</time_frame>
    <description>Minimu:0, Maximum: 18, Higher scores mean a worse vascular outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hachinski ischemic score total score</measure>
    <time_frame>Day 24 month</time_frame>
    <description>Minimu:0, Maximum: 18, Higher scores mean a worse vascular outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alzheimer's Disease Assessment Scale-cognitive section (ADAS-Cog) total score</measure>
    <time_frame>Day 0</time_frame>
    <description>Minimu:0, Maximum: 70, Higher scores mean a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alzheimer's Disease Assessment Scale-cognitive section (ADAS-Cog) total score</measure>
    <time_frame>Day 24 month</time_frame>
    <description>Minimu:0, Maximum: 70, Higher scores mean a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alzheimer's Disease Assessment Scale-activities of daily living section (ADCS-ADL) total score</measure>
    <time_frame>Day 0</time_frame>
    <description>Minimu:0, Maximum: 54, Higher scores mean a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alzheimer's Disease Assessment Scale-activities of daily living section (ADCS-ADL) total score</measure>
    <time_frame>Day 24 month</time_frame>
    <description>Minimu:0, Maximum: 54, Higher scores mean a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geriatric Depression Scale (GDS) total score</measure>
    <time_frame>Day 0</time_frame>
    <description>Minimu:0, Maximum: 15, Higher scores mean a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geriatric Depression Scale (GDS) total score</measure>
    <time_frame>Day 24 month</time_frame>
    <description>Minimu:0, Maximum: 15, Higher scores mean a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Life- Alzheimer Dementia (QOL-AD) total score</measure>
    <time_frame>Day 0</time_frame>
    <description>Minimu:13, Maximum: 52, Higher scores mean a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Life- Alzheimer Dementia (QOL-AD) total score</measure>
    <time_frame>Day 24 month</time_frame>
    <description>Minimu:13, Maximum: 52, Higher scores mean a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MRI examination 1</measure>
    <time_frame>Day 0</time_frame>
    <description>Total brain volume: MRI examination will be performed on the 1.5 Telsla machine (GE, USA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MRI examination 2</measure>
    <time_frame>Day 24 months</time_frame>
    <description>Total brain volume: MRI examination will be performed on the 1.5 Telsla machine (GE, USA)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">163</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Dementia Disorder</condition>
  <arm_group>
    <arm_group_label>EPA and DHA intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EPA 1000mg and DHA 1000mg capsule twice a day, the total exposure to the intervention for each subject is 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPA intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EPA 2000mg capsule twice a day, the total exposure to the intervention for each subject is 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DHA intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DHA 2000mg capsule twice a day, the total exposure to the intervention for each subject is 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 2000mg capsule twice a day, the total exposure to the intervention for each subject is 24 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>EPA</intervention_name>
    <description>EPA 2000mg Soft capsules</description>
    <arm_group_label>EPA and DHA intervention</arm_group_label>
    <arm_group_label>EPA intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>DHA</intervention_name>
    <description>DHA 2000mg Soft capsules</description>
    <arm_group_label>DHA intervention</arm_group_label>
    <arm_group_label>EPA and DHA intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Soft capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients may be included in the study if they meet the following criteria:&#xD;
&#xD;
               1. Males and females over 65 years of age.&#xD;
&#xD;
               2. Diagnosis of Alzheimer's Dementia disorder.&#xD;
&#xD;
               3. Each individual must have a level of understanding sufficient to perform all&#xD;
                  tests and examinations required.&#xD;
&#xD;
               4. Individuals must be willing to accept all laboratory examinations and MRI&#xD;
                  examination.&#xD;
&#xD;
               5. Individuals must be willing to provide a small sample of blood for evaluation.&#xD;
&#xD;
               6. Individuals must be willing to participate in a short 30-60 minute clinical&#xD;
                  interview.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients may be excluded from the study for any of the following reasons:&#xD;
&#xD;
               1. Serious unstable illness such that death is anticipated within 1 year or&#xD;
                  intensive care unit hospitalization for the condition is anticipated within 6&#xD;
                  months.&#xD;
&#xD;
               2. Diagnosis of Vascular Dementia disorder.&#xD;
&#xD;
               3. Uncorrected hypothyroidism or hyperthyroidism&#xD;
&#xD;
               4. Participants will be excluded if they had evidence of epilepsy; focal brain&#xD;
                  lesion; head injury with loss of consciousness or confusion after the injury;&#xD;
                  DSMIV-TR (text revision) criteria for any major psychiatric disorder including&#xD;
                  psychosis, major depression, bipolar disorder, or alcohol or substance abuse; or&#xD;
                  potential bleeding tendency.&#xD;
&#xD;
               5. History of allergy to fish or omega-3 polyunsaturated fatty acids.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>105 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tsuo-Hung Lan, MD, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Yang Ming University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <state>No.450,Sec.1,Dongda Rd.,Xitun Dist.</state>
        <zip>40764</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M; Alzheimer's Disease International. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005 Dec 17;366(9503):2112-7.</citation>
    <PMID>16360788</PMID>
  </reference>
  <reference>
    <citation>World Alzheimer Report 2010. Alzheimer's Disease International, 2010.</citation>
  </reference>
  <reference>
    <citation>Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 2007 Jul;3(3):186-91. doi: 10.1016/j.jalz.2007.04.381.</citation>
    <PMID>19595937</PMID>
  </reference>
  <reference>
    <citation>Daviglus ML, Bell CC, Berrettini W, Bowen PE, Connolly ES Jr, Cox NJ, Dunbar-Jacob JM, Granieri EC, Hunt G, McGarry K, Patel D, Potosky AL, Sanders-Bush E, Silberberg D, Trevisan M. National Institutes of Health State-of-the-Science Conference statement: preventing alzheimer disease and cognitive decline. Ann Intern Med. 2010 Aug 3;153(3):176-81. doi: 10.7326/0003-4819-153-3-201008030-00260. Epub 2010 Jun 14.</citation>
    <PMID>20547888</PMID>
  </reference>
  <reference>
    <citation>Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 2011 Sep;10(9):819-28. doi: 10.1016/S1474-4422(11)70072-2. Epub 2011 Jul 19. Review.</citation>
    <PMID>21775213</PMID>
  </reference>
  <reference>
    <citation>Wang XD, Kashii S, Zhao L, Tonchev AB, Katsuki H, Akaike A, Honda Y, Yamashita J, Yamashima T. Vitamin B6 protects primate retinal neurons from ischemic injury. Brain Res. 2002 Jun 14;940(1-2):36-43.</citation>
    <PMID>12020872</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 8, 2018</study_first_submitted>
  <study_first_submitted_qc>July 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taichung Veterans General Hospital</investigator_affiliation>
    <investigator_full_name>Tsuo-Hung Lan</investigator_full_name>
    <investigator_title>Department of Psychiatry, Taichung Veterans General Hospital</investigator_title>
  </responsible_party>
  <keyword>Dementia Alzheimer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

